This report provides a comprehensive analysis of the global contraceptive devices market, which is projected to experience steady growth through 2033. Driven by increasing sexual health awareness and proactive government family planning initiatives, the market is characterized by diverse product types, with condoms maintaining a dominant position due to their affordability and dual protection. While North America holds a significant market share, the Asia-Pacific region is emerging as the fastest-growing segment, fueled by massive population demands and expanding reproductive healthcare access.

Executive Overview

The global contraceptive devices market reached US$ 10.98 billion in 2024 and is projected to reach US$ 19.37 billion by 2033, growing at a CAGR of 6.6% during the forecast period of 2025-2033.

Definition and Purpose: Contraceptive devices are physical products designed to prevent pregnancy by either obstructing sperm from reaching an egg or altering the body’s hormonal or physical environment to make pregnancy less likely. These devices come in various forms and can be used by both men and women. They represent one of the most common methods of birth control, alongside hormonal methods such as pills or injections. Contraceptive devices serve as a critical solution in family planning, reproductive health, and population control.

Market Drivers: The demand for contraceptive devices has been steadily increasing worldwide, driven by a combination of demographic, social, economic, and healthcare-related factors. This growing demand is primarily influenced by:

• The desire for better family planning.
• More effective control over reproduction.
• Increasing awareness of sexual health.
• Novel product launches (e.g., in September 2024, ConTIPI Medical partnered with EVERSANA to support the US commercial launch of the ProVate device).

Market Dynamics

Drivers: Rising Awareness and Government Initiatives

Rising awareness and government initiatives are significantly driving the growth of the contraceptive devices market and are expected to drive the market over the forecast period. Governments worldwide are prioritizing family planning as a key aspect of public health, recognizing its direct impact on economic development, healthcare costs, and gender equality. Many countries have launched national family planning programs to make contraceptive devices more accessible and affordable.

• India: The National Family Planning Program has been a cornerstone of the country's contraceptive distribution efforts to reduce population growth. Through government subsidies and awareness campaigns, millions have been introduced to modern methods. In 2020, India saw an increase in the use of long-acting reversible contraceptives (LARCs) such as IUDs and implants.
• Awareness Campaigns: Efforts spearheaded by governments or NGOs bring crucial information to underserved and rural areas, emphasizing benefits and combating myths/misinformation. This education, particularly for young people and women, removes barriers to use.
• United States: Organizations like Planned Parenthood run education programs to raise awareness about reproductive health options. In 2021, over 2.4 million people in the U.S. used contraceptive services provided by Planned Parenthood.

Restraints: Side Effects and Health Concerns

While providing significant benefits, side effects and health concerns remain key factors that can hamper market growth, leading to hesitancy or discontinuation of use.

• Hormonal Side Effects: Many popular devices, including IUDs (intrauterine devices), implants, and vaginal rings, release hormones. While highly effective, these can cause side effects that deter continued use.
• Procedural Risks: There are associated risks of infection and uterine perforation upon insertion, particularly if not performed in a sterile environment or by trained professionals.
• Long-term Concerns: Some individuals express concern regarding the long-term impact of hormonal methods on fertility or increased cancer risk. While these fears (such as delayed return to normal fertility) are often based on misinformation or outdated studies, they still impact market adoption.

Segment Analysis

The global contraceptive devices market is segmented based on product type, technology, gender, distribution channel, and region.

Product Type

• Condoms: This segment is expected to dominate the contraceptive devices market. Dominance is driven by:
• Affordability and Ease of Use: Low cost makes them accessible to a wide demographic, including low-income populations. Many countries offer free or subsidized condoms through public health initiatives.
• Dual Protection: Unlike IUDs or hormonal contraceptives, condoms are the only method that provides protection against both pregnancy and sexually transmitted infections (STIs), including HIV, chlamydia, and gonorrhea.
• STI Prevention Impact: According to the World Health Organization, 374 million new STI infections occurred globally among adults aged 15–49 involving one of the four curable STIs (syphilis, chlamydia, gonorrhea, and trichomoniasis), most of which could be prevented with correct condom use.

Geographical Analysis

North America

North America is expected to hold a significant position in the contraceptive devices market with the highest market share.

• High Awareness: The region boasts high levels of education regarding family planning and sexual health. Comprehensive sex education in the U.S. and Canada ensures clear understanding of methods and benefits.
• Usage Statistics: According to the Guttmacher Institute, 99% of women aged 15-44 in the U.S. who have had sex have used at least one contraceptive method, with 75% using modern methods like IUDs, implants, and condoms.
• Government Support: Active promotion through subsidies and public health programs, such as the U.S. federal Title X program which funds family planning clinics.

Asia-Pacific

Asia-Pacific is growing at the fastest pace in the contraceptive devices market.

• Demographic Demand: The region holds the world's largest population (over 4.6 billion people, or ~60% of the global population). High population density in countries like China and India creates substantial demand for family planning.
• India Case Study: With over 1.4 billion people, India's demand is rising as families manage birth rates. The National Family Health Survey (NFHS) indicates over 50% of married women in India use modern contraceptive methods (IUDs, condoms, oral pills). The government promotes this via programs like Mission Parivar Vikas.
• Policy Support: Regional governments use national programs to distribute devices and improve maternal health, directly contributing to market growth.

Competitive Landscape

The major global players in the contraceptive devices market include:

• Abbvie Inc.
• Bayer AG
• CooperSurgical, Inc.
• EUROGINE, S.L.
• Mona Lisa N.V.
• OCON Medical Ltd.
• Pregna International Limited
• Prosan International BV
• Reckitt Benckiser Group
• Veru Inc.

Report Value Proposition

Why Purchase the Report?

• Pipeline & Innovations: Reviews clinical trials, product pipelines, and upcoming advancements.
• Product Performance & Market Positioning: Analysis to optimize growth strategies.
• Real-World Evidence: Integration of patient feedback into development.
• Physician Preferences & Health System Impact: Examination of provider behaviors and system mergers.
• Market Updates & Industry Changes: Coverage of regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analysis of competitor market share and emerging players.
• Pricing & Market Access: Review of pricing models, reimbursement, and access strategies.
• Market Entry & Expansion: Identification of optimal entry strategies and partnerships.
• Regional Growth & Investment: Highlighting high-growth regions and opportunities.
• Supply Chain Optimization: Assessment of risks and distribution efficiency.
• Sustainability & Regulatory Impact: Focus on eco-friendly practices and evolving healthcare regulations.
• Post-market Surveillance: Using data to enhance product safety.
• Pharmacoeconomics & Value-Based Pricing: Analysis of the shift toward data-driven R&D and value-based models.

Report Details:

• Total Pages: 163
• Key Tables: 70
• Visual Figures: 64+

Target Audience

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

• 1 Market Introduction and Scope

  • 1.1 Objectives of the Report

  • 1.2 Report Coverage & Definitions

  • 1.3 Report Scope

• 2 Executive Insights and Key Takeaways

  • 2.1 Market Highlights and Strategic Takeaways

  • 2.2 Key Trends and Future Projections

  • 2.3 Snippet by Product Type

  • 2.4 Snippet by Technology

  • 2.5 Snippet by Gender

  • 2.6 Snippet by Distribution Channel

  • 2.7 Snippet by Region

• 3 Dynamics

  • 3.1 Impacting Factors

    • 3.1.1 Drivers

      • 3.1.1.1 Increasing Awareness and Government Initiatives
      • 3.1.1.2 Rising Advancements in Contraceptive Devices

    • 3.1.2 Restraints

      • 3.1.2.1 Side Effects and Health Concerns
      • 3.1.2.2 High Cost of Contraceptive Devices

    • 3.1.3 Opportunity

      • 3.1.3.1 Government Initiatives
      • 3.1.3.2 XX

    • 3.1.4 Impact Analysis

• 4 Strategic Insights and Industry Outlook

  • 4.1 Market Leaders and Pioneers

    • 4.1.1 Emerging Pioneers and Prominent Players

    • 4.1.2 Established leaders with largest selling Brand

    • 4.1.3 Market leaders with established Product

  • 4.2 CXO Perspectives

  • 4.3 Latest Developments and Breakthroughs

  • 4.4 Case Studies/Ongoing Research

  • 4.5 Regulatory and Reimbursement Landscape

    • 4.5.1 North America

    • 4.5.2 Europe

    • 4.5.3 Asia Pacific

    • 4.5.4 Latin America

    • 4.5.5 Middle East & Africa

  • 4.6 Porter’s Five Forces Analysis

  • 4.7 Supply Chain Analysis

  • 4.8 Patent Analysis

  • 4.9 SWOT Analysis

  • 4.10 Unmet Needs and Gaps

  • 4.11 Recommended Strategies for Market Entry and Expansion

  • 4.12 Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts

  • 4.13 Pricing Analysis and Price Dynamics

  • 4.14 Key Opinion Leaders

• 5 Contraceptive Devices Market, By Product Type

  • 5.1 Introduction

    • 5.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 5.1.2 Market Attractiveness Index, By Product Type

  • 5.2 Condoms*

    • 5.2.1 Introduction

    • 5.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 5.3 Diaphragms and Cervical Caps

  • 5.4 Sponges

  • 5.5 Vaginal Rings

  • 5.6 Intrauterine Devices (IUDs)

  • 5.7 Sub-dermal Implants

• 6 Contraceptive Devices Market, By Technology

  • 6.1 Introduction

    • 6.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

    • 6.1.2 Market Attractiveness Index, By Technology

  • 6.2 Hormonal Contraceptives*

    • 6.2.1 Introduction

    • 6.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 6.3 Barrier Contraceptives

• 7 Contraceptive Devices Market, By Gender

  • 7.1 Introduction

    • 7.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

    • 7.1.2 Market Attractiveness Index, By Gender

  • 7.2 Male*

    • 7.2.1 Introduction

    • 7.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 7.3 Female

• 8 Contraceptive Devices Market, By Distribution Channel

  • 8.1 Introduction

    • 8.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

    • 8.1.2 Market Attractiveness Index, By Distribution Channel

  • 8.2 Hospital Pharmacies*

    • 8.2.1 Introduction

    • 8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 8.3 Retail Pharmacies

  • 8.4 Online Channels

  • 8.5 Others

• 9 Contraceptive Devices Market, By Regional Market Analysis and Growth Opportunities

  • 9.1 Introduction

    • 9.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

    • 9.1.2 Market Attractiveness Index, By Region

  • 9.2 North America

    • 9.2.1 Introduction

    • 9.2.2 Key Region-Specific Dynamics

    • 9.2.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 9.2.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

    • 9.2.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

    • 9.2.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

    • 9.2.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 9.2.7.1 U.S
      • 9.2.7.2 Canada
      • 9.2.7.3 Mexico

  • 9.3 Europe

    • 9.3.1 Introduction

    • 9.3.2 Key Region-Specific Dynamics

    • 9.3.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 9.3.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

    • 9.3.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

    • 9.3.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

    • 9.3.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 9.3.7.1 Germany
      • 9.3.7.2 U.K
      • 9.3.7.3 France
      • 9.3.7.4 Spain
      • 9.3.7.5 Italy
      • 9.3.7.6 Rest of Europe

  • 9.4 South America

    • 9.4.1 Introduction

    • 9.4.2 Key Region-Specific Dynamics

    • 9.4.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 9.4.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

    • 9.4.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

    • 9.4.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

    • 9.4.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 9.4.7.1 Brazil
      • 9.4.7.2 Argentina
      • 9.4.7.3 Rest of South America

  • 9.5 Asia-Pacific

    • 9.5.1 Introduction

    • 9.5.2 Key Region-Specific Dynamics

    • 9.5.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 9.5.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

    • 9.5.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

    • 9.5.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

    • 9.5.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 9.5.7.1 China
      • 9.5.7.2 India
      • 9.5.7.3 Japan
      • 9.5.7.4 South Korea
      • 9.5.7.5 Rest of Asia-Pacific

  • 9.6 Middle East and Africa

    • 9.6.1 Introduction

    • 9.6.2 Key Region-Specific Dynamics

    • 9.6.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

    • 9.6.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

    • 9.6.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

    • 9.6.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

• 10 Competitive Landscape and Market Positioning

  • 10.1 Competitive Overview and Key Market Players

  • 10.2 Market Share Analysis and Positioning Matrix

  • 10.3 Strategic Partnerships, Mergers & Acquisitions

  • 10.4 Key Developments in Product Portfolios and Innovations

  • 10.5 Company Benchmarking

• 11 Company Profiles

  • 11.1 CooperSurgical, Inc.*

    • 11.1.1 Company Overview

    • 11.1.2 Product Portfolio and Description

    • 11.1.3 Financial Overview

    • 11.1.4 Key Developments

    • 11.1.5 SWOT Analysis

  • 11.2 Pregna International Limited

  • 11.3 Reckitt Benckiser group

  • 11.4 Veru Inc

  • 11.5 Bayer AG

  • 11.6 Abbvie Inc

  • 11.7 EUROGINE, S.L

  • 11.8 Mona Lisa N.V

  • 11.9 Prosan International BV

  • 11.10 OCON Medical Ltd

• 12 Assumption and Research Methodology

  • 12.1 Data Collection Methods

  • 12.2 Data Triangulation

  • 12.3 Forecasting Techniques

  • 12.4 Data Verification and Validation

• 13 Appendix

  • 13.1 About Us and Services

  • 13.2 Contact Us